Posted by Michael Wonder on 01 Aug 2022
Pharming receives accelerated assessment in Europe for leniolisib for the treatment of rare immunodeficiency, APDS
1 August 2022 - Pharming is on track to submit its marketing authorisation application for leniolisib in H2 2022.
Pharming announces that the EMA's CHMP has granted an accelerated assessment for the marketing authorisation application for leniolisib.
